Table 2.
Distribution of membrane staining results among primary tumours of renal cancer patients treated for metastatic disease with sunitinib or sorafenib in first or second line setting
| Extent (circumference) of stained membrane and distribution | ||
| EXTENT SCORE | PERCENTAGE STAINED | NUMBER OF CASES |
| 0 | 0-10% | 44 |
| 1 | 11-80% | 6 |
| 2 | 81-100% | 56 |
| Fraction of stained membrane and distribution | ||
| FRACTION SCORE | PERCENTAGE STAINED | NUMBER OF CASES |
| 0 | 0-1% | 48 |
| 1 | 2-25% | 16 |
| 2 | 26-50% | 21 |
| 3 | 51-75% | 10 |
| 4 | 76-100% | 11 |
| Combined score (addition of extent and fraction score) and distribution | ||
| COMBINED SCORE | NUMBER OF CASES | |
| 0 | 44 | |
| 1 | 1 | |
| 2 | 6 | |
| 3 | 15 | |
| 4 | 19 | |
| 5 | 10 | |
| 6 | 11 | |
| PKLR negative and positive cases | ||
| PKLR EXPRESSION | NUMBER OF CASES | |
| (-) | 51 | |
| (+) | 55 | |